What podcasts say about Richard Francis

Every statement, with the speaker, the exact quote and the moment it was said.

What Richard Francis has said on podcasts

10 statements · 9 positive · 1 negative

on Teva neurology and CNS medicinesPositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva has developed treatments targeting schizophrenia, migraine, and tardive dyskinesia.
“we're very proud that we've taken on schizophrenia, we've taken on migraine, we've taken on tardive dyskinesia.”
Listen at 30:36
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Teva AustedoPositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva expects Austedo peak sales of $3 billion.
“we have peak sales of 3 billion.”
Listen at 31:08
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Tardive dyskinesia treatmentNegativeJan 29, 2026· Mad Money w/ Jim Cramer
Eighty-five percent of relevant patients remain untreated.
“85% of patients are still not on treatment.”
Listen at 31:15
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Teva Huntington’s disease treatmentPositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva’s treatment can substantially improve patients’ quality of life.
“it can really transform the quality of life.”
Listen at 31:37
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Teva migraine productPositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva’s migraine product grew 30% in 2025 and is forecast to grow substantially next year.
“In 2025, it was up 30%. And now we've given a forecast next year that has tremendous growth in it.”
Listen at 32:01
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Teva UZEDYPositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva’s UZEDY grew 63% last year.
“that was up 63 percent last year.”
Listen at 33:20
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Teva long-acting olanzapinePositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva’s long-acting olanzapine could transform schizophrenia treatment.
“when we launch... LAI, our long-acting olanzapine, I think we have a real opportunity to transform the treatment for those patients.”
Listen at 33:50
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Teva product pipelinePositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva expects to launch four products within five years.
“we're going to have an opportunity to launch. four products in five years.”
Listen at 34:43
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Teva pipeline milestonesPositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva expects seven innovative milestones in 2026.
“we have seven milestones this year, and they're all innovative.”
Listen at 34:55
Open the episode · Mad Money w/ Jim Cramer 1/28/26
on Teva scientific capabilitiesPositiveJan 29, 2026· Mad Money w/ Jim Cramer
Teva’s scientific capabilities have been substantially underestimated.
“the quality of science we have at Teva, I think, has been way underestimated.”
Listen at 35:34
Open the episode · Mad Money w/ Jim Cramer 1/28/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.